Added to YB: 2026-04-01
Pitch date: 2026-03-30
CABA [neutral]
Cabaletta Bio, Inc.
+7.6%
current return
Author Info
No bio for this author
Company Info
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases.
Market Cap
$298.3M
Pitch Price
$2.50
Price Target
N/A
Dividend
N/A
EV/EBITDA
-1.15
P/E
-1.28
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
CABA Update: FDA Pushes Back on Myositis Trial Design
CABA (update): FDA flagged March '26 concerns on external registry comparator for 17-pt single-arm Myositis trial due to baseline differences. Rejection could force RCT, killing 2027 BLA timeline & requiring more capital. $133.6M cash, $167.9M burn; raised $30M via ATM/warrants, runway to Q4 '26. 1H '26 data readouts key catalyst. CAAR platform intact across Lupus/SSc/MG/Myositis; strong efficacy could salvage single-arm design or attract M&A if standalone path too costly.
Read full article (2 min)